Resources

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.To share any updates or corrections to the snapshot, please contact rsvsnapshot@path.org.

This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention.Sources of information for these trials are clinicaltrials.gov; who.int/clinical-trials-registry-platform; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.To share any updates or corrections to the tracker, please contact rsvsnapshot@path.org.

PATH’s Living Labs Initiative uses human-centered design (HCD) to co-create sustainable health solutions in partnership with the intended users. Organizations that are interested in deeply engaging with health workers, communities, and other public health stakeholders to design and test innovations that increase health system capacity and advance health equity will find information below on how to partner with Living Labs to accelerate and creatively address their priorities. We offer a range of service models and partnerships, and this playbook outlines those options.

PATH and CEPI hosted a webinar on May 22, 2025, as a forum for researchers to present current work on biobanking for pandemic response, strengthen existing and new collaborations, and share experiences and lessons learned with the broader research community. Presentations included:An Introduction to the Coalition for Epidemic Preparedness Innovations (CEPI) Biospecimen Sourcing Initiative (Selorm Avumegah, CEPI)CEPI Perspectives on the Pandemic Agreement (Austin Liu, CEPI)Perspective on the Development of Respectful Partnerships and Aligning Stakeholder Goals With the Overall Aims of Biobanks (Daniel Simeon-Dubach, MedService)Strategies for Rapid Deployability in Biobanking: International Agency for Research on Cancer’s Experiences in Implementing Rapid Collection Initiatives (Zisis Kozlakidis, International Agency for Research on Cancers/World Health Organization)Access and Sharing Regional-Representative Characterized Specimens in a Federated and Distributed Biorepository System: The Need for Data Harmonization Across Sites and Standard Protocols (May Chu and Thomas Jaenisch, Colorado School of Public Health)

This report provides data and information on the current and projected global autodisable (AD) syringe market. It includes a PATH forecast of AD syringe demand from 2025 through 2028, which estimates a need for nearly 2 billion AD syringes in 2025 and relatively small fluctuations in global demand through 2028. Additionally, the report includes information about current market events (such as recent outbreaks), innovations (such as microarray patches), and key stakeholder interests that may impact the AD syringe market in the near future.